
RCUS Valuation
Arcus Biosciences Inc
- Overview
- Forecast
- Valuation
- Earnings
RCUS Relative Valuation
RCUS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RCUS is overvalued; if below, it's undervalued.
Historical Valuation
Arcus Biosciences Inc (RCUS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 7.21 is considered Undervalued compared with the five-year average of -6.30. The fair price of Arcus Biosciences Inc (RCUS) is between 174.07 to 195.31 according to relative valuation methord. Compared to the current price of 9.74 USD , Arcus Biosciences Inc is Undervalued By 94.4%.
Relative Value
Fair Zone
174.07-195.31
Current Price:9.74
94.4%
Undervalued
-2.17
PE
1Y
3Y
5Y
Trailing
Forward
-0.34
EV/EBITDA
Arcus Biosciences Inc. (RCUS) has a current EV/EBITDA of -0.34. The 5-year average EV/EBITDA is -4.29. The thresholds are as follows: Strongly Undervalued below -14.02, Undervalued between -14.02 and -9.15, Fairly Valued between 0.58 and -9.15, Overvalued between 0.58 and 5.45, and Strongly Overvalued above 5.45. The current Forward EV/EBITDA of -0.34 falls within the Historic Trend Line -Fairly Valued range.
-0.32
EV/EBIT
Arcus Biosciences Inc. (RCUS) has a current EV/EBIT of -0.32. The 5-year average EV/EBIT is -3.17. The thresholds are as follows: Strongly Undervalued below -10.50, Undervalued between -10.50 and -6.83, Fairly Valued between 0.50 and -6.83, Overvalued between 0.50 and 4.16, and Strongly Overvalued above 4.16. The current Forward EV/EBIT of -0.32 falls within the Historic Trend Line -Fairly Valued range.
7.21
PS
Arcus Biosciences Inc. (RCUS) has a current PS of 7.21. The 5-year average PS is 15.66. The thresholds are as follows: Strongly Undervalued below -3.92, Undervalued between -3.92 and 5.87, Fairly Valued between 25.45 and 5.87, Overvalued between 25.45 and 35.24, and Strongly Overvalued above 35.24. The current Forward PS of 7.21 falls within the Historic Trend Line -Fairly Valued range.
-2.44
P/OCF
Arcus Biosciences Inc. (RCUS) has a current P/OCF of -2.44. The 5-year average P/OCF is -8.21. The thresholds are as follows: Strongly Undervalued below -45.59, Undervalued between -45.59 and -26.90, Fairly Valued between 10.48 and -26.90, Overvalued between 10.48 and 29.17, and Strongly Overvalued above 29.17. The current Forward P/OCF of -2.44 falls within the Historic Trend Line -Fairly Valued range.
-2.55
P/FCF
Arcus Biosciences Inc. (RCUS) has a current P/FCF of -2.55. The 5-year average P/FCF is -7.87. The thresholds are as follows: Strongly Undervalued below -33.91, Undervalued between -33.91 and -20.89, Fairly Valued between 5.15 and -20.89, Overvalued between 5.15 and 18.17, and Strongly Overvalued above 18.17. The current Forward P/FCF of -2.55 falls within the Historic Trend Line -Fairly Valued range.
Arcus Biosciences Inc (RCUS) has a current Price-to-Book (P/B) ratio of 2.04. Compared to its 3-year average P/B ratio of 2.34 , the current P/B ratio is approximately -12.63% higher. Relative to its 5-year average P/B ratio of 2.75, the current P/B ratio is about -25.93% higher. Arcus Biosciences Inc (RCUS) has a Forward Free Cash Flow (FCF) yield of approximately -27.97%. Compared to its 3-year average FCF yield of -10.24%, the current FCF yield is approximately 173.20% lower. Relative to its 5-year average FCF yield of -4.81% , the current FCF yield is about 481.72% lower.
1.96
P/B
Median3y
2.34
Median5y
2.75
-27.97
FCF Yield
Median3y
-10.24
Median5y
-4.81
Competitors Valuation Multiple
The average P/S ratio for RCUS's competitors is 796.97, providing a benchmark for relative valuation. Arcus Biosciences Inc Corp (RCUS) exhibits a P/S ratio of 7.21, which is -99.10% above the industry average. Given its robust revenue growth of -80.69%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of RCUS decreased by 41.44% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -2.76 to -400.00.
The secondary factor is the Revenue Growth, contributed -80.69%to the performance.
Overall, the performance of RCUS in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch

ATUS
Altice USA Inc
2.550
USD
-2.67%

NSSC
NAPCO Security Technologies Inc
30.890
USD
-0.45%

INMD
Inmode Ltd
14.310
USD
-1.58%

HCI
Hci Group Inc
138.310
USD
+0.09%

DCBO
Docebo Inc
30.180
USD
-2.83%

SMWB
Similarweb Ltd
8.680
USD
-1.81%

AGL
agilon health inc
1.930
USD
-3.02%

AIV
Apartment Investment and Management Co
8.670
USD
+0.81%

LEU
Centrus Energy Corp
224.080
USD
-6.40%

ALEX
Alexander & Baldwin Inc (Hawaii)
18.520
USD
+1.37%
FAQ

Is Arcus Biosciences Inc (RCUS) currently overvalued or undervalued?
Arcus Biosciences Inc (RCUS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 7.21 is considered Undervalued compared with the five-year average of -6.30. The fair price of Arcus Biosciences Inc (RCUS) is between 174.07 to 195.31 according to relative valuation methord. Compared to the current price of 9.74 USD , Arcus Biosciences Inc is Undervalued By 94.40% .

What is Arcus Biosciences Inc (RCUS) fair value?

How does RCUS's valuation metrics compare to the industry average?

What is the current P/B ratio for Arcus Biosciences Inc (RCUS) as of Jul 30 2025?

What is the current FCF Yield for Arcus Biosciences Inc (RCUS) as of Jul 30 2025?

What is the current Forward P/E ratio for Arcus Biosciences Inc (RCUS) as of Jul 30 2025?
